Illumina, Inc. $ILMN Shares Sold by Casdin Capital LLC

Casdin Capital LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 18.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 525,000 shares of the life sciences company’s stock after selling 120,000 shares during the quarter. Illumina comprises about 4.2% of Casdin Capital LLC’s investment portfolio, making the stock its 7th biggest position. Casdin Capital LLC owned 0.34% of Illumina worth $49,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Generali Asset Management SPA SGR boosted its holdings in Illumina by 51.6% in the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after acquiring an additional 7,574 shares during the period. Aaron Wealth Advisors LLC grew its position in Illumina by 342.6% in the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after acquiring an additional 8,109 shares in the last quarter. Elo Mutual Pension Insurance Co purchased a new stake in shares of Illumina during the third quarter valued at approximately $2,319,000. Douglas Lane & Associates LLC raised its stake in shares of Illumina by 6.6% during the third quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock valued at $29,214,000 after purchasing an additional 18,914 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Illumina by 148.6% during the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after purchasing an additional 19,519 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. decreased their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Canaccord Genuity Group boosted their price objective on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a report on Monday, January 26th. Barclays upped their price objective on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $129.69.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

Illumina Stock Up 2.9%

ILMN stock opened at $118.94 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $18.19 billion, a P/E ratio of 21.82, a PEG ratio of 2.28 and a beta of 1.45. The firm has a 50 day simple moving average of $133.15 and a 200-day simple moving average of $119.96.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the firm earned $0.95 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.